AMCP Partnership Forum Addresses Gaps in Adoption of Precision Medicine

AMCP Partnership Forum Addresses Gaps in Adoption of Precision Medicine 

Alexandria, Va., June 26, 2025 — Last week, AMCP convened a diverse group of stakeholders for its Precision Medicine Partnership Forum to examine solutions that improve access, consistency, and quality in precision oncology. Attendees included patients, payers, pharmacy benefit managers, providers, pathologists, laboratory benefit managers, and leaders from advocacy organizations, coalitions, and professional associations. The multi-session event focused on aligning clinical guidelines, diagnostics, and managed care processes to ensure that innovation in cancer care leads to meaningful, equitable outcomes for patients. 

Forum participants explored persistent challenges across the precision medicine access ecosystem, particularly in oncology. Experts pointed to fragmentation and misalignment as key contributors to care gaps, using the example of non-small cell lung cancer (NSCLC), and emphasized the need for system-level changes that better inform clinical decision making, reduce time to initiation with targeted therapies, and support guideline-concordant care. 

Attendees recommended deeper collaboration between clinical organizations and managed care to support the uptake of biomarker testing, standardize a vernacular for stakeholders, and develop national quality standards to ensure clinical utility and enhance patient outcomes.  

“We need to accelerate how we align care with clinical evidence, advance pathologist-initiated biomarker testing at diagnosis, and elevate precision medicine to improve patient outcomes,” said AMCP CEO Susan Cantrell, RPh, CAE. “The more precise the treatment, the better the likelihood that a patient reaches a successful outcome. Getting the right people together for these critical conversations is essential to AMCP’s mission to ensure patients get the therapies they need at a cost they can afford.” 

AMCP will carry the momentum forward by integrating precision medicine across its research, advocacy, education, and convening platforms, including Nexus 2025, AMCP 2026, and virtual training opportunities. Additional efforts include collaborating with key partners, including the National Comprehensive Cancer Network (NCCN), the Association of Cancer Care Centers (ACCC), the Association for Molecular Pathology (AMP), and the American Society for Clinical Pathology (ASCP), to continue to address precision medicine care gaps.

AMCP would like to thank Valuate Health Consultancy for assisting with the development and moderation of the Forum.  Thank you to our generous sponsors: AbbVie, AstraZeneca, Genentech, Illumina, Johnson & Johnson, KlearTrust, Lilly, Merck, Pfizer, and Sanofi. Their support for this vital topic paves the way for more equitable and accessible treatment plans in oncology and beyond.

To learn more about AMCP’s precision medicine initiatives, visit our Precision Medicine Landing Page.    

About AMCP  

AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.